Sep 30 |
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
|
Sep 25 |
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
|
Sep 18 |
With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing
|
Sep 3 |
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
|
Aug 12 |
Caribou Biosciences appoints Albertson as CMO
|
Aug 12 |
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
|
Aug 8 |
Caribou Biosciences Second Quarter 2024 Earnings: Beats Expectations
|
Aug 6 |
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 6 |
Caribou Bioscience GAAP EPS of -$0.42 beats by $0.04, revenue of $3.46M beats by $0.42M
|
Aug 6 |
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
|